Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890462613> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2890462613 endingPage "7034" @default.
- W2890462613 startingPage "7034" @default.
- W2890462613 abstract "7034 Background: In a phase II study in 50 elderly patients (pts) with AML who were not eligible for intensive chemotherapy, treatment with pracinostat + azacitidine (AZA) was well tolerated, led to 42% complete remission (CR) rate and a median overall survival (OS) of 19.1 months (Blood 2016: 128;100). Here we investigate the impact of somatic mutations and their clearance on disease response and patient outcomes. Methods: 88 samples from 41 study pts were sequenced. All 41 pts were analyzed pre-treatment, and a median of 3 longitudinal samples were analyzed from 19 pts between Cycle 2 and 9. Mutations were assayed by SureSelect targeted capture exon sequencing (Agilent) of 295 genes that are recurrently mutated in hematologic malignancies. Longitudinal mutation clearance was analyzed by plotting variant allele frequency (VAF). Results: At baseline, 96 mutations in 28 genes were detected in 38 pts, with the most frequent being in SRSF2 (27%), DNMT3A (20%), IDH2 (17%), RUNX1 (17%), and TET2(17%). Mutations associated with CR rate and OS are indicated in the Table. A CR was achieved in 10/19 pts that had longitudinal sequencing analysis and at the time of CR, 9 (90%) had persistently detectable mutations in their bone marrow. In 7 of them, continued exposure to pracinostat + AZA lowered the VAF or cleared residual mutations. In 2 pts, relapsed samples showed re-expansion of the founder clone. Conclusions: Mutations in NPM1, and DNA methylation pathway were associated with a better response to pracinostat + AZA, while TP53 mutation was associated with a poor response. Persistent mutation at the time of CR suggests residual preleukemic clonal hematopoiesis in this elderly population. Benefit of prolonged exposure to pracinostat + AZA was also confirmed at molecular level where continued decline of mutation VAF was seen after achieving CR. Clinical trial information: NCT01912274. [Table: see text]" @default.
- W2890462613 created "2018-09-27" @default.
- W2890462613 creator A5002527534 @default.
- W2890462613 creator A5011595056 @default.
- W2890462613 creator A5014892222 @default.
- W2890462613 creator A5028729197 @default.
- W2890462613 creator A5051949215 @default.
- W2890462613 creator A5061026876 @default.
- W2890462613 creator A5063691844 @default.
- W2890462613 creator A5072463255 @default.
- W2890462613 creator A5074297763 @default.
- W2890462613 date "2017-05-20" @default.
- W2890462613 modified "2023-10-15" @default.
- W2890462613 title "Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat." @default.
- W2890462613 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.7034" @default.
- W2890462613 hasPublicationYear "2017" @default.
- W2890462613 type Work @default.
- W2890462613 sameAs 2890462613 @default.
- W2890462613 citedByCount "2" @default.
- W2890462613 countsByYear W28904626132019 @default.
- W2890462613 crossrefType "journal-article" @default.
- W2890462613 hasAuthorship W2890462613A5002527534 @default.
- W2890462613 hasAuthorship W2890462613A5011595056 @default.
- W2890462613 hasAuthorship W2890462613A5014892222 @default.
- W2890462613 hasAuthorship W2890462613A5028729197 @default.
- W2890462613 hasAuthorship W2890462613A5051949215 @default.
- W2890462613 hasAuthorship W2890462613A5061026876 @default.
- W2890462613 hasAuthorship W2890462613A5063691844 @default.
- W2890462613 hasAuthorship W2890462613A5072463255 @default.
- W2890462613 hasAuthorship W2890462613A5074297763 @default.
- W2890462613 hasConcept C104317684 @default.
- W2890462613 hasConcept C126322002 @default.
- W2890462613 hasConcept C143998085 @default.
- W2890462613 hasConcept C150194340 @default.
- W2890462613 hasConcept C190727270 @default.
- W2890462613 hasConcept C2483381 @default.
- W2890462613 hasConcept C2776239401 @default.
- W2890462613 hasConcept C2778729363 @default.
- W2890462613 hasConcept C2779823535 @default.
- W2890462613 hasConcept C2780007613 @default.
- W2890462613 hasConcept C30481170 @default.
- W2890462613 hasConcept C45091340 @default.
- W2890462613 hasConcept C501734568 @default.
- W2890462613 hasConcept C502942594 @default.
- W2890462613 hasConcept C53226629 @default.
- W2890462613 hasConcept C54355233 @default.
- W2890462613 hasConcept C71924100 @default.
- W2890462613 hasConcept C86803240 @default.
- W2890462613 hasConceptScore W2890462613C104317684 @default.
- W2890462613 hasConceptScore W2890462613C126322002 @default.
- W2890462613 hasConceptScore W2890462613C143998085 @default.
- W2890462613 hasConceptScore W2890462613C150194340 @default.
- W2890462613 hasConceptScore W2890462613C190727270 @default.
- W2890462613 hasConceptScore W2890462613C2483381 @default.
- W2890462613 hasConceptScore W2890462613C2776239401 @default.
- W2890462613 hasConceptScore W2890462613C2778729363 @default.
- W2890462613 hasConceptScore W2890462613C2779823535 @default.
- W2890462613 hasConceptScore W2890462613C2780007613 @default.
- W2890462613 hasConceptScore W2890462613C30481170 @default.
- W2890462613 hasConceptScore W2890462613C45091340 @default.
- W2890462613 hasConceptScore W2890462613C501734568 @default.
- W2890462613 hasConceptScore W2890462613C502942594 @default.
- W2890462613 hasConceptScore W2890462613C53226629 @default.
- W2890462613 hasConceptScore W2890462613C54355233 @default.
- W2890462613 hasConceptScore W2890462613C71924100 @default.
- W2890462613 hasConceptScore W2890462613C86803240 @default.
- W2890462613 hasIssue "15_suppl" @default.
- W2890462613 hasLocation W28904626131 @default.
- W2890462613 hasOpenAccess W2890462613 @default.
- W2890462613 hasPrimaryLocation W28904626131 @default.
- W2890462613 hasRelatedWork W1579836645 @default.
- W2890462613 hasRelatedWork W1986006429 @default.
- W2890462613 hasRelatedWork W2016587546 @default.
- W2890462613 hasRelatedWork W2150690129 @default.
- W2890462613 hasRelatedWork W2167468830 @default.
- W2890462613 hasRelatedWork W2193596267 @default.
- W2890462613 hasRelatedWork W2766065220 @default.
- W2890462613 hasRelatedWork W2774443367 @default.
- W2890462613 hasRelatedWork W3138153931 @default.
- W2890462613 hasRelatedWork W4220922874 @default.
- W2890462613 hasVolume "35" @default.
- W2890462613 isParatext "false" @default.
- W2890462613 isRetracted "false" @default.
- W2890462613 magId "2890462613" @default.
- W2890462613 workType "article" @default.